Monoamine Oxidase Inhibitors: Prescription and Patient Management
- 1 June 1981
- journal article
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
- Vol. 10 (2) , 99-121
- https://doi.org/10.2190/uvvy-h0n2-b7v1-mhw0
Abstract
The historical roots of the current avoidance of MAOIs are reviewed. A practical approach to the careful prescription of MAOIs is outlined. Medical contraindications, side effects and their management and drug and food interactions with MAOIs are discussed. With careful patient selection, adequate caution by the physician, and appropriate preparation of the patient, MAOIs are often uniquely effective (as in endogenous anxiety) and have an acceptably low potential for serious toxicity.Keywords
This publication has 27 references indexed in Scilit:
- Death after Taking MedicamentsBMJ, 1974
- ACETYLATOR STATUS AND RESPONSE TO PHENELZINE IN DEPRESSED PATIENTSThe Lancet, 1973
- Phenelzine in phobic anxiety: a controlled trialPsychological Medicine, 1973
- Diagnostic Criteria for Use in Psychiatric ResearchArchives of General Psychiatry, 1972
- Multiple Forms of Rat Brain Monoamine OxidaseNature, 1969
- Hypertensive Interactions Between Monoamine Oxidase Inhibitors and FoodstuffsThe British Journal of Psychiatry, 1967
- Clinical Trial of the Treatment of Depressive IllnessBMJ, 1965
- Treatment of Depression: A Comparative Study of E.C.T. and Six DrugsThe British Journal of Psychiatry, 1963
- Effects of Iproniazid in Depressive SyndromesBMJ, 1959
- Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymesCellular and Molecular Life Sciences, 1952